Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203)-Reference-Cited by-同舟云学术

Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203)

Published:2017-12-06 Issue:4 Volume:124 Page:688-697
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Meropol Neal J.¹,Feng Yang²,Grem Jean L.³^ORCID,Mulcahy Mary F.⁴,Catalano Paul J.⁵,Kauh John S.⁶,Hall Michael J.⁷,Saltzman Joel N.⁸,George Thomas J.⁹,Zangmeister Jeffrey¹⁰,Chiorean Elena G.¹¹,Cheema Puneet S.¹²,O'Dwyer Peter J.¹³,Benson Al B.⁴

Affiliation:

1. Case Comprehensive Cancer Center; Case Western Reserve University; Cleveland Ohio

2. Department of Biostatistics and Computational Biology; Dana Farber Cancer Institute; Boston Massachusetts

3. Hematology/Oncology; University of Nebraska Medical Center; Omaha Nebraska

4. Department of Medical Oncology; Northwestern University; Chicago Illinois

5. Department of Biostatistics; Dana Farber Cancer Institute/Harvard Cancer Center; Boston Massachusetts

6. Department of Medicine; Emory University; Atlanta Georgia

7. Clinical Genetics and Medical Oncology; Fox Chase Cancer Center; Philadelphia Pennsylvania

8. Seidman Cancer Center; Lake Health University Hospitals; Mentor Ohio

9. Division of Hematology/Oncology University of Florida; Gainesville Florida

10. Hematology/Oncology; Mount Carmel Health Center West; Columbus Ohio

11. Hematology/Oncology; Indiana University; Indianapolis Indiana

12. Department of Medical Oncology; Abbott-Northwestern Hospital; Minneapolis Minnesota

13. Department of Oncology; University of Pennsylvania; Philadelphia Pennsylvania

Funder

National Cancer Institute

Sanofi-Aventis

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference29 articles.

1. Intratumoral or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer;Grem;Semin Oncol.,2005

2. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin;Leichman;J Clin Oncol.,1997

3. Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy;Kornmann;Cancer Lett.,1997

4. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy;Aschele;J Clin Oncol.,1999

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Redefining the Incidence and Profile of Fluoropyrimidine-Associated Cardiotoxicity in Cancer Patients: A Systematic Review and Meta-Analysis;Pharmaceuticals;2023-03-30

2. Regulation of thymidylate synthase: an approach to overcome 5-FU resistance in colorectal cancer;Medical Oncology;2022-10-29

3. Lipid-Based Nanoparticle Formulation of Diallyl Trisulfide Chemosensitizes the Growth Inhibitory Activity of Doxorubicin in Colorectal Cancer Model: A Novel In Vitro, In Vivo and In Silico Analysis;Molecules;2022-03-28

4. Efficacy and Safety of Systemic Treatments Among Colorectal Cancer Patients: A Network Meta-Analysis of Randomized Controlled Trials;Frontiers in Oncology;2022-02-09

5. The Effect of Liposomal Diallyl Disulfide and Oxaliplatin on Proliferation of Colorectal Cancer Cells: In Vitro and In Silico Analysis;Pharmaceutics;2022-01-20